# Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion

> **NCT03223714** · PHASE3 · COMPLETED · sponsor: **Chengdu Kanghong Biotech Co., Ltd.** · enrollment: 242 (actual)

## Conditions studied

- Macular Edema
- Central Retinal Vein Occlusion

## Interventions

- **DRUG:** Conbercept Ophthalmic Injection
- **DRUG:** sham injection

## Key facts

- **NCT ID:** NCT03223714
- **Lead sponsor:** Chengdu Kanghong Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-24
- **Primary completion:** 2020-04-13
- **Final completion:** 2020-09-28
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2022-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03223714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03223714, "Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03223714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*